Zobrazeno 1 - 10
of 85
pro vyhledávání: '"A. Oaknin"'
Autor:
Kathleen N. Moore, Amit M. Oza, Conleth G. Murphy, Nicoletta Colombo, Giovanni Scambia, J. Wang, P.C. Lim, Jason A. Konner, Bradley J. Monk, Anna Berkenblit, Michael J. Birrer, Patricia Pautier, H. Hirte, M. Prasad-Hayes, Ana Oaknin, Ignace Vergote, Susana Banerjee, Domenica Lorusso, Janos L. Tanyi, Gottfried E. Konecny
Publikováno v:
Scientia
Chemotherapy; Mirvetuximab soravtansine; Ovarian cancer Quimioterapia; Mirvetuximab soravtansina; Cáncer de ovarios Quimioteràpia; Mirvetuximab soravtansina; Càncer d'ovaris Background Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab500045f9eb68bf0669cf8d0f50c90f
https://lirias.kuleuven.be/handle/20.500.12942/692015
https://lirias.kuleuven.be/handle/20.500.12942/692015
Autor:
Romero, Octavio A., Vilarrubi, Andrea, Alburquerque-Béjar, Juan Jos, Gómez Moruno, Antonio, Andrades, Álvaro, Trastulli, Deborah, Pros, Eva, Setien, Fernando, Verdura, Sara, Farre, Lourdes, Martín-Tejera, Juan F., Llabata, Paula, Oaknin, Ana, Saigi, María, Piulats, Josep M., Matias-Guiu, Xavier, Medina, Pedro P., Vidal, August, Villanueva, Alberto, Sanchez-Cespedes, Montse, Universitat Autònoma de Barcelona
Publikováno v:
Nature Communications
Dipòsit Digital de la UB
Universidad de Barcelona
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Digibug. Repositorio Institucional de la Universidad de Granada
instname
Scientia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Dipòsit Digital de la UB
Universidad de Barcelona
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Digibug. Repositorio Institucional de la Universidad de Granada
instname
Scientia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The authors thank Isabel Bartolessis (Cancer Genetics Group) at IJC for technical assistance. This work was supported by the Spanish Ministry of Economy and CompetitivityMINECO (grant number SAF-2017-82186R, to M.S.-C., and grant PI19/01320 to A. Vil
Autor:
Giovanni Scambia, Andrew R Clamp, Ana Oaknin, Susana Banerjee, Terri Cameron, David M. O'Malley, Nicoletta Colombo, Robert L. Coleman, Jonathan A. Ledermann, Andrew Dean, Amit M. Oza, Domenica Lorusso, Jeffrey C. Goh, Margarita Amenedo Gancedo, Jesús García-Donas, Johanne I Weberpals, Robert W. Holloway, Sandra Goble, Alexandra Leary, Elizabeth M. Swisher, Deborah K. Armstrong, Peter C.C. Fong, Carol Aghajanian
Publikováno v:
Int J Gynecol Cancer
IntroductionIn ARIEL3 (NCT01968213), the poly(adenosine diphosphate-ribose) polymerase inhibitor rucaparib significantly improved progression-free survival versus placebo regardless of biomarker status when used as maintenance treatment for recurrent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c04ef495b5cab90306c251bb18fd5030
https://europepmc.org/articles/PMC9445915/
https://europepmc.org/articles/PMC9445915/
Autor:
Ritu Salani, Leslie M. Randall, Krishnansu S. Tewari, Mario M. Leitao, David W. Kindelberger, Michael W. Sill, David H. Moore, James J. Burke, Eric L. Eisenhauer, Paul DiSilvestro, Helen Michael, Michael L. Pearl, Debra L. Richardson, Richard T. Penson, Linda Van Le, Heather A. Lankes, Bradley J. Monk, Lisa M. Landrum, Michael J. Birrer, Ana Oaknin, Lois M. Ramondetta
Publikováno v:
Mol Cancer Ther
To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1 and 36 day
Autor:
Redondo Sánchez, Andrés, Oaknin, Ana, Rubio, Maria Jesus, Barretina-Ginesta, Maria-Pilar, de Juan, Ana, Manso, Luis, Romero, Ignacio, Martin-Lorente, Cristina, Poveda, Andres, Gonzalez-Martin, Antonio, Universitat Autònoma de Barcelona
Publikováno v:
Journal of Ovarian Research
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-12 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-12 (2021)
Background To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8e868e5b05a2396ff6f5a9000a18703
https://hdl.handle.net/10668/17837
https://hdl.handle.net/10668/17837
Autor:
Andrew R Clamp, Giovanni Scambia, Jesús García-Donas, Robert W. Holloway, Amit M. Oza, Juliette Meunier, Nicoletta Colombo, Robert L. Coleman, Lara Maloney, Alexandra Leary, Margarita Amenedo Gancedo, Ana Oaknin, David M. O'Malley, Sandra Goble, Josh Bedel, Deborah K. Armstrong, Peter C.C. Fong, Jeffrey C. Goh, Carol Aghajanian, Domenica Lorusso, Johanne I Weberpals, Elizabeth M. Swisher, Jonathan A. Ledermann, Susana Banerjee, Terri Cameron, Andrew Dean
Publikováno v:
Scientia
Gynecologic oncology
Gynecologic oncology
Pacients d'edat avançada; Càncer d'ovaris; Inhibidor de la PARP Pacientes de edad avanzada; Cáncer de ovarios; Inhibidor de PARP Elderly patients; Ovarian cancer; PARP inhibitor Background In the phase 3 trial ARIEL3, maintenance treatment with th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d7005aea5c1c77d6850dc9f329a5a6
http://hdl.handle.net/10807/167340
http://hdl.handle.net/10807/167340
Autor:
Peter C.C. Fong, Ann Christin Mörk, Carol Aghajanian, Giovanni Scambia, David Cella, Josh Bedel, Deborah K. Armstrong, Juliette Meunier, Robert W. Holloway, Ana Oaknin, Lara Maloney, Alexandra Leary, Johanne I Weberpals, Margarita Amenedo Gancedo, Elizabeth M. Swisher, Andrew R Clamp, Jeffrey C. Goh, Sandra Goble, Andrew Dean, Domenica Lorusso, David M. O'Malley, Jesús García-Donas, Amit M. Oza, Susana Banerjee, Terri Cameron, Jonathan A. Ledermann, Nicoletta Colombo, Robert L. Coleman
Publikováno v:
Journal of Clinical Oncology
Scientia
Scientia
Carcinoma d'ovari recurrent; Rucaparib Carcinoma de ovario recurrente; Rucaparib Recurrent Ovarian Carcinoma; Rucaparib PURPOSE To investigate quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de4b91b79cf28241c1fc82a95b633d4d
http://hdl.handle.net/10281/291278
http://hdl.handle.net/10281/291278
Autor:
Ling Ma, Tanya T. Kwan, Clare L. Scott, Isabelle Ray-Coquard, Ana Oaknin, Alexander Dobrovic, Robert L. Coleman, Iain A. McNeish, Andrea E. Wahner Hendrickson, Lee-may Chen, Alexandra Leary, Stephen Welch, Thomas Harding, Lara Maloney, Carol Aghajanian, Kevin K. Lin, Heidi Giordano, E. Dominy, Ashan Musafer, Gottfried E. Konecny, Scott H. Kaufmann, Diane Provencher, Julia A. Elvin, Oliver Dorigo, Sandra Goble, R Kristeleit, Douglas I. Lin, Anna V. Tinker, Amit M. Oza, Setsuko K. Chambers, David M. O'Malley, Elizabeth M. Swisher, Prafull Ghatage, Lan Thanh Vo
Publikováno v:
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Scientia
Nature communications, vol 12, iss 1
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Scientia
ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD5
Autor:
Alla Lisyanskaya, Giovanni Scambia, Amit M. Oza, Ralph Bloomfield, Cara Mathews, Paul DiSilvestro, Alexandra Leary, Michael Friedlander, Ana Oaknin, Anne Floquet, Nicoletta Colombo, Carol Aghajanian, Susana Banerjee, Kathleen N. Moore, William H. Bradley, Elizabeth S. Lowe, Byoung Gie Kim, Antonio González-Martín, Gabe S. Sonke, Charlie Gourley, Joyce F. Liu
Publikováno v:
Moore, K, Colombo, N, Scambia, G, Kim, B-G, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, Gonzalez-Martin, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Lowe, E S, Bloomfield, R & DiSilvestro, P 2018, ' Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer ', New England Journal of Medicine, vol. 379, no. 26, pp. 2495-2505 . https://doi.org/10.1056/NEJMoa1810858
BACKGROUND: Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor
Autor:
Jeff Bruce, Ainhoa Madariaga, Iulia Cirlan, Tiantiam Li, Amit M. Oza, Stephanie Lheureux, Swati Garg, Neesha C. Dhani, Ana Oaknin, Stephanie Pedersen, Marsela Braunstein, Qian Tan, Sarah Accardi, Katherine Karakasis, Justin White, Valerie Bowering, Trevor J. Pugh, Lorena Fariñas-Madrid, Yeh Chen Lee, Zhihui Amy Liu
Publikováno v:
Clinical Cancer Research. 26:4206-4215
Purpose:PARP inhibitors (PARPi) are standard-of-care therapy for high-grade serous ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with olaparib (PARPi) at emergence of PARPi resistance.Patients and Methods:The proof-of-c